ProCE Banner Activity

FAQs: Incorporating Novel and Emerging Treatment Combinations Into the Management of Aggressive B-Cell Lymphomas

Clinical Thought
In this commentary, expert faculty address frequently asked questions about incorporating novel and emerging treatment combinations into the management of MCL and DLBCL.

Released: July 28, 2022

Expiration: July 27, 2023

No longer available for credit.

Share

Faculty

Julie M. Vose

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Jeremy S. Abramson

Jeremy S. Abramson, MD, MMSc

Director, Hagler Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Grzegorz Nowakowski

Grzegorz Nowakowski, MD

Professor of Medicine and Oncology
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Genmab US

Incyte Corporation

Lilly

Program Director Disclosure

Program Director

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA: consultant: AbbVie, AstraZeneca, Daiichi Sankyo, Genentech, Janssen, Lilly, MEI Pharma.

Faculty Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc

Director, Hagler Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc: consultant: AbbVie, AstraZeneca, BeiGene, Bluebird, Bristol-Myers Squibb, Century, Epizyme, Genentech, Genmab, Incyte, Kite, Kymera, Lilly, MorphoSys, Mustang, Ono, Regeneron.

Grzegorz Nowakowski, MD

Professor of Medicine and Oncology
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Grzegorz Nowakowski, MD: consultant: AbbVie, ADC Therapeutics, Bantam, Blueprint Medicines, Bristol-Myers Squibb, Celgene Corporation, Curis, Debiopharm, F. Hoffmann-La Roche, Fate Therapeutics, Genentech, Incyte, Karyopharm Therapeutics, Kite Pharma, Kymera Therapeutics, MEI Pharma, MorphoSys, Ryvu Therapeutics, Seagen, Selvita, TG Therapeutics, Zai Lab.